|
|
Article: Ovarian Cancer: platinum-based therapy still the gold standard.
- Article from:
- M2 Presswire
- Article date:
- September 8, 2006
CopyrightCOPYRIGHT 2006 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-8 September 2006-DATAMONITOR: Ovarian Cancer: platinum-based therapy still the gold standard(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:08092006
London - Despite being the most common cause of death from gynecological tumors, ovarian cancer does not attract the same level of Rinterest from pharmaceutical and biotech companies as more prevalent tumor types like breast, lung or colorectal cancer. However, nearly 60,000 cases of ovarian cancer are being diagnosed in the seven major markets* each year, and although five-year survival rates have been trending upwards, prognosis deteriorates as the disease progresses until by stage IV, the five year ...